Systemic Therapy for Melanoma
Key Points
Key Points
- The clinical burden associated with the treatment of melanoma has been increasing due to rising incidence globally.
- Since 2011, 12 new drugs have been approved for unresectable melanoma and 4 additional drugs have been approved in the adjuvant setting.
- Overall survival for melanoma is improving rapidly, with dramatic increases in long-term survival observed from administration of these new therapies.
- This guideline includes recommendations on uveal melanoma based on new clinical trial data.
Treatment
...Treatme...
...Neoadjuvant Sys...
...Cutaneous Me...
...mendation 1.1.Neoadjuvant pembrolizumab (max...
...n 1.2.Patients with clinical and res...
...Adjuvant Syste...
...Resected (Stage I...
...ecommendation 2.1.1.Adjuvant pembrolizumab or...
....1.2.Adjuvant therapy should not be offered to...
...n 2.2.For patients with resected stage IIIA...
...ecommendation 2.3.For patients with resected sta...
....4.No recommendation can be made for or agai...
...n 2.5.1.Patients with resected sta...
...mendation 2.5.2....
...mab alone (Evidence Quality - Medium) (...
...ipilimumab followed by nivolumab ( IC ,...
...rolizumab alone ( IC , L , , W...
...plus trametinib (in patients with BRAF V600E...
...System...
...Un...
...dation 3.1.For patients with BRAF wild-type, unr...
...3.2.1.For patients with BRAF mutant (V600)...
...endation 3.2.2....
...rapy with nivolumab plus ipilimumab is...
...therapy with nivolumab plus ipilimumab is pr...
...endation 3.3.After progression on anti-...
...mendation 3.4.After progression on 1st lin...
...on 3.5.For patients with injectable (...
...Non-Cutaneous Me...
...dation 4.1.1.HLA-A*02:01-positive pat...
...4.1.2.For all patients with uveal melanoma other t...
...on 4.2.In the absence of further data, t...
...dation 4.3.No recommendation for or against any s...
...le 1. Reasonable Dose and Schedule...
...le 2. Reasonable Dose and Schedule...
.... Systemic Therapy for Melanoma...
Figure 1. Systemic Therapy for Mela...